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Ethanol-Based Proliposome Delivery Systems of Paclitaxel for In Vitro 
Application Against Brain Cancer Cells  
In this study the anticancer activity of paclitaxel-loaded nano-liposomes on glioma 
cell lines was investigated. Soya phosphatidylcholine: cholesterol (SPC:Chol), 
hydrogenated soya phosphatidylcholine: cholesterol (HSPC:Chol) or 
dipalmitoylphosphatidylcholine: cholesterol (DPPC:Chol) in 1:1 mole ratio were 
used to prepare ethanol-based proliposomes. Following hydration of proliposomes, 
the size of resulting vesicles was subsequently reduced to nanometre scale via 
probe-sonication. The resulting formulations were characterised in terms of size, 
zeta potential and morphology of the vesicles, and entrapment efficiency of 
paclitaxel (PX) as well as the final pH of the preparations. DPPC-liposomes 
entrapped 35-92% of PX compared to 27-74% and 25-60% entrapped by liposomes 
made from SPC and HSPC formulations respectively, depending on drug 
concentration. The entrapment efficiency of liposomes was dependent on the lipid 
bilayer properties and ability of PX to modify surface charge of the vesicles. In 
vitro cytotoxicity studies revealed that PX-liposome formulations were more 
selective at inhibiting the malignant cells. The cytotoxicity of PX-liposomes was 
dependent on their drug entrapment efficiency. This study has shown PX-
liposomes generated from proliposomes have selective activity against glioma cell 
lines, and the synthetic DPPC phospholipid was most suitable for maximised drug 
entrapment and highest activity against the malignant cells in vitro. 
Keywords: proliposome; entrapment efficiency; cytotoxicity; phospholipids; 
paclitaxel; cell culture  
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Introduction   
Paclitaxel (PX) has been reported to demonstrate a significant anticancer activity against 
ovarian carcinoma, head and neck cancers, breast cancer, lung cancer and AIDS related 
Kaposi’s sarcoma (Rowinsky and Donehower, 1995). Despite its promising efficacy, the 
clinical use of paclitaxel is limited by its poor water-solubility as well as low cellular 
permeability (Wani et al., 1971, Panchagnula, 1998, Singla et al., 2002, Yoshizawa et al., 
2014). For clinical administration of paclitaxel, the drug is dissolved in Cremophor® EL 
(Poly-oxyethylated castor oil) and ethanol (50:50 v/v) followed by dilution by 5-20 times 
before parenteral injection; the marketed formulation with this vehicle system is Taxol®. 
Unfortunately, Cremophor EL causes serious toxic effects such as nephrotoxicity, 
hypersensitivity reactions, neurotoxicity, laboured breathing, hypotension and lethargy 
(Singla et al., 2002). Therefore, replacing Cremophor® EL by a biocompatible 
formulation that can also increase aqueous solubility and improve therapeutic efficacy of 
the drug is highly needed (Kadam et al., 2014). Abraxane® is an FDA approved 
nanomedicine formulation of paclitaxel attached with albumin nanoparticles (Garber, 
2004). Clinical investigations have demonstrated that Abraxane® can offer 14% higher 
response rate and 33% greater tumour penetration than Taxol® (Garber, 2004). However, 
obtaining large quantities of human albumin is expensive, thus designing alternative 
nanomedicines that are safe and economically affordable is highly desirable.   
Liposomal-based formulations have been suggested as ‘non-toxic’ 
nanomedicines, owing to the great similarity of the liposomal phospholipids 
with biological membranes; this makes liposomes highly biocompatible and 
biodegradable (Crosasso et al., 2000, Koudelka and Turánek, 2012). 
Incorporation of PX in liposomes can reduce the drug toxicity to normal 
tissues and eliminate the hypersensitivity reactions caused by Cremophor EL 
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vehicle. Liposomes also reduce the dose-limiting toxicity of PX by significant 
elevation of the maximum tolerated dose (MTD) of the drug (Sharma et al., 
1993, Cabanes et al., 1998, Fetterly and Straubinger, 2003).  
Intracranial administration of liposomal paclitaxel in rat brain tumor model 
has shown to increase the life span in the animals to up to 40% compared to 
cremophor EL and ethanol mixture formulations (Zhou et al., 2010). Lipusu® 
(Luye Pharma Group) is a paclitaxel liposomal formulation that has recently 
been commercialized and recommended for the treatment of breast, ovarian 
and non-small cell lung cancer (Koudelka and Turánek, 2012, Wang et al., 
2013).  
A major limitation of liposomes is their poor stability, owing to oxidation and 
hydrolysis of the phospholipids. Proliposome technologies such as 
particulate-based proliposomes (Payne et al., 1986a, Payne et al., 1986b) and 
ethanol (solvent)-based proliposomes (Perrett et al., 1991) have been 
advocated to overcome the instability manifestations of liposomes and 
provide convenient and economic options when compared to spray-drying or 
freeze-drying of liposomes. Ethanol-based proliposomes are ethanolic lipid 
solutions which, depending on the hydration procedure, generate 
oligolamellar liposomes (Perrett et al., 1991) or multilamellar vesicles 
(Turánek et al., 1997). Proliposomes can also offer a feasible approach for 
manufacturing liposome precursors on a large scale,(Gala et al., 2015) thus 
overcoming the instability problems (liability of phospholipid to hydrolysis, 
oxidation and subsequent leakage of entrapped drug), high costs and 
unsuitability of conventional thin-film made liposomes for large scale 
production (Kensil and Dennis, 1981, Grit et al., 1989).  
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Liposomes prepared by ethanol-based proliposome method have been shown 
to provide high entrapment efficiency for hydrophilic drugs. The entrapment 
efficiency ranged from 60 to 80% depending on the composition of 
phospholipid (Perrett et al., 1991) and 30 to 85% depending on the hydration 
protocol of the proliposomes (Turánek et al., 1997, Elhissi et al., 2006). 
Noteworthy, that hydration temperature employed was important at 
influencing the entrapment efficiency as high temperature (60°C) provided 
an effective entrapment (approx. 80%) rather than at low temperature (20°C) 
where the entrapment was around 50% (Turánek et al., 1997). Hydrophobic 
drugs may also have high entrapment efficiencies in these liposomes. 
Entrapment efficiencies of 93 to 98% have been reported for levonorgestrel 
depending on type of alcohol employed in the formulation (Deo et al., 1997). 
In this study, we have introduced paclitaxel-loaded liposomes prepared via 
the ethanol-based proliposome technology using various lipid compositions. 
Physicochemical properties of formulations such as size, size distribution, 
zeta potential, pH, vesicle morphology and drug entrapment efficiency were 
studied. Moreover, the cytotoxicity of the formulations on grade IV glioma 
(U87-MG) and normal glial (SVG-P12) cell lines was investigated.   
Methods 
Materials  
Soya phosphatidylcholine (SPC; Lipoid S-100), hydrogenated phosphatidylcholine 
(HSPC; Phospholipon 90H) and dipalmitoyl phosphatidylcholine (DPPC) were obtained 
from Lipoid, Switzerland. EMEM (Eagle’s minimum essential medium), non-essential 
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amino acid solution and L-glutamine (cell culture tested, 99.0 – 101.0 %) were purchased 
from Lonza, Switzerland. Trypsin-EDTA solution, ethanol (absolute and 70%), 96-well 
plates (sterile with lids), 50 ml centrifuge tubes (sterile), tissue culture flask 75 cm2 
(sterile) and serological pipettes (sterile) were obtained from Fisher Scientific, UK.  
Cholesterol (Chol; ≥ 99%), glass vials (15 ml), poly-L-lysine (PLL) hydrobromide 
(molecular weight 30,000-70,000), dextran (molecular weight 5,000 approx.), Dimethyl 
sulfoxide (DMSO), thiazolyl blue tetrazolium bromide, Fetal bovine serum (FBS), 
Phosphate buffered saline (PBS) tablets, Trypan blue solution (0.4% liquid, sterile 
filtered), Syringe filters (0.2 and 0.45 µm), syringe needles and sterile pipette tip boxes 
were all purchased from Sigma Aldrich, UK. Human glioblastome cell line (U87-MG) 
and Human glial cell line (SVG-P12) were obtained from European collection of cell 
cultures, UK. Paclitaxel (PX) was purchased from ChemieTek, USA.  
Preparation of Liposomes  
The lipid phase (phospholipid: Chol, 1:1 mole ratio) (50 mg) was dissolved in absolute 
ethanol (75 μl) at 70°C (water bath) for 1 min within a 15 ml glass vial. Paclitaxel was 
then added in the ethanolic solution to produce a range of concentrations in the subsequent 
aqueous dispersion (0.1, 0.3, 0.5 and 1 mg per ml of the final liposomal dispersion). 
Aqueous (water) phase (10 ml), significantly above the Tm of the lipid was added 
immediately to avoid lipid phase solidification. Liposomes were generated upon vigorous 
hand shaking and vortex mixing (Fisons Whirlimixer, UK) for 4 min. Liposomal 
formulations were then kept for annealing above the Tm of the lipids for 2 h followed by 
size, zeta potential measurements and electron microscopy studies.  
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Size Reduction of Liposomes 
Liposome dispersions (10 ml) were probe-sonicated (Sonics Vibra-cell-CV33, USA) at 
the highest frequency for a maximum of 10 min with intermittent cooling to avoid 
excessive heating of the liposomes. The resultant dispersion (except for those of the 
entrapment determination) was centrifuged (Jouan Robotics A-14, France) at 10,000 rpm 
(9,200 g) for 2 min to remove the titanium particles leached from the probe of the 
sonicator.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Laser Diffraction Size Analysis for Liposomes Before Size Reduction 
Laser diffraction technique was used for size analysis of liposomes. The measurements 
were performed using the Malvern Mastersizer 2000 (Malvern instruments Ltd., UK). 
This was carried out by addition of 70 ml of deionised water to the cone dispersion unit 
(Hydro2000 SM, UK) of the instrument. Size and size distribution were presented as the 
volume median diameter (VMD) (50% undersize) and Span respectively. Span = (90% 
undersize – 10% undersize) / VMD.  
Photon Correlation Spectroscopy (PCS) Analysis After Size Reduction 
Photon correlation spectroscopy (PCS) technique relies on the Brownian motion of the 
particles using the Zetasizer instrument (Zetasizer nano, Malvern Instruments Ltd., UK). 
The size and polydispersity of the sonicated liposomes (in the supernatant; i.e. following 
removal of titanium particles) were analyzed by recording the hydrodynamic diameter 
(Zaverage) and polydispersity index (PI) respectively using the Zetasizer instrument 
(Zetasizer nano, Malvern Instruments Ltd., UK). 
Determination of Drug Entrapment Efficiency 
Entrapment efficiency of PX was determined by adapting the separation methods 
previously used by Kumar et al (2001) and Gala et al (Gala et al., 2015). Liposome 
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suspension was passed through syringe filters (0.45 µm) at least three times. The filter 
was then washed with HPLC water until the solution ran clear. Then, the filter was placed 
in absolute ethanol and paclitaxel was extracted. The extracted fraction was collected to 
determine the proportion of un-entrapped drug using Dionex Ultimate 3000 UHPLC with 
BetaBasic column 18 particle size 5µm, pore size 150A, 150mm L x 4.6mm I.D. Mobile 
phase; acetonitrile: water:methanol (55:45:5) at wavelength 227nm, retention time was 
5.6 min. This amount was subtracted from the total amount of PX in the liposomes to 
calculate the amount of entrapped drug. The solubility of paclitaxel in water is less than 
0.1 μg/mL (Konno et al., 2003), therefore, the amount of the drug dissolved in water 
during hydration was ignored. The entrapment efficiency (EE) of paclitaxel (PX) in 
liposomes was calculated using the following equation: 
 
𝐸𝐸 (%) =
Amount of PX entrapped
Total amount of PX in liposome formulation
x 100 
Cytotoxicity Study (MTT Assay) 
The U87-MG cells (grade IV glioma, passage 13) and SVG-P12 (glial cells, passage 7) 
were seeded at 1 x105 cells/well in 96-well plates and maintained at 37oC in an 
atmosphere of 5% CO2 and 95% relative humidity in Eagle’s minimum essential medium 
(EMEM) supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine and 
0.1 mM non-essential amino acids. Prior to assay, loaded liposomal formulations of 1 
mg/ml were filtered through a 0.4 µm sterile syringe filters to remove unloaded paclitaxel. 
Considering the loading efficiency (Figure 5), filtered formulations were used as stocks 
diluted by media to yield 1, 2.5, 5, 25, 50, 250, 500, 1500 nM of loaded paclitaxel.  
After 24 h of incubation, the cells were washed in PBS solution, and 200 µl 
of medium containing tested formulations each at range of concentrations was 
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added (traces of DMSO (up to 0.3%) were used to solubilise free PX in warm 
medium at 37°C). After 72 h of incubation at 37oC, 20 µl of 3-(4,5-
dimethythiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 
mg/ml) was added and cells incubated for a further 5 h. Medium was 
removed, and 100 µl dimethylsulfoxide (DMSO) was added and incubated 
for further 30 min at 37oC. Then, the optical density at 570 nm was measured 
(Tecan GENios Plus, Switzerland). The level of colour development in the 
control wells (containing only medium) was assumed to indicate 100% 
viability). The IC50 values (i.e. concentration resulting in 50% inhibition of 
cell growth) of the liposomes and paclitaxel were calculated graphically from 
the cell viability curves obtained by considering the absorbance of the media 
containing cells as 100% (Yang et al., 2007). 
Statistical Analysis  
Statistical significance was measured using the one-way analysis of variance (ANOVA) 
and student’s t-tests as appropriate. All values were expressed as the mean ± standard 
deviation. Values of P < 0.05 were regarded as significantly different. 
Results and Discussion 
 
Size Analysis and Microscopic Morphology of Liposomes Before Sonication 
The influence of paclitaxel concentration and phospholipid composition on size 
distribution of the liposomes generated from ethanol-based proliposomes was 
investigated. Figure 1a shows the effect of paclitaxel concentration on the VMD of the 
formulated liposomes. The VMD of SPC-liposomes containing PX at 0.5 mg/ml (3.78 ± 
0.08 µm) and 1 mg/ml (3.83 ± 0.09 µm) concentrations were larger than VMD of 
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paclitaxel-free SPC-liposomes (3.12 ± 0.07 µm) (P<0.05). However, the VMD of PX-
SPC-liposomes containing low PX concentration showed no significant difference when 
compared to that of PX-free SPC-liposomes (P>0.05). This suggests that the VMD of 
SPC-liposomes was increased by increasing drug concentration (0.5 and 1 mg/ml) but not 
at lower PX concentrations (0.1 and 0.3 mg/ml). 
The VMDs of HSPC-liposomes containing PX were higher than that of drug-
free HSPC-liposomes (P<0.05) (Figure 1a). Moreover, continuous increase 
in the size of HSPC-liposomes was observed as the concentration of PX was 
increased. Similarly, the VMD of all PX-DPPC-liposomes were significantly 
larger than drug-free DPPC-liposomes (P<0.05). Figure 1a shows that HSPC-
liposome size was almost doubled because of drug inclusion at the maximum 
concentration of 1 mg/ml within formulation. The VMD of all PX-DPPC-
liposomes increased by increasing paclitaxel concentration but not as high as 
that observed with PX-HSPC-liposomes (Figure 1a). 
The VMD measurements of HSPC-based liposomes were higher than those 
of the corresponding DPPC-based liposomes (P<0.05). Amongst the 
phospholipids used, PX concentration was most influential to the size of 
vesicles made from HSPC:Chol (1:1). This is possibly attributed to the higher 
hydrophobicity of the longer acyl chains in HSPC phospholipid and repulsive 
interactions between water molecules at the interface, causing the vesicles to 
aggregate (Zhao and Feng, 2004, Zhao and Feng, 2005, Zhao et al., 2007). 
Size distribution of liposomes was represented by the measurement of Span, 
a term introduced by Malvern Instruments Ltd to express the polydispersity 
of particles. In general, no effect was seen on the Span of liposome 
formulations when PX was included, and the Span values for all formulations 
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were around 2 (Figure 1b). The only exception was the Span of liposomes 
made from SPC:Chol (1:1) which increased (P<0.05) by inclusion of 0.1 
mg/ml PX. However, no further increase of SPC-made liposomes was 
observed by inclusion of higher drug concentrations. Drug concentration did 
not affect the Span of HSPC-liposomes or DPPC liposomes (P>0.05; Figure 
1b).  
TEM studies have shown that liposomes prior to probe-sonication were 
multilamellar vesicles (MLVs) and that was independent of drug 
concentration or lipid composition (images not shown). This agrees with our 
previous publication of liposomes prepared using the ethanol-based 
proliposome technology (Elhissi et al., 2006). Studies by other investigators 
have shown that liposomes generated from ethanol-based proliposomes were 
oligolamellar (Perrett et al., 1991) or multilamellar (Turánek et al., 1997).  
Size Analysis of Liposomes After Sonication 
Size of liposomes was reduced aiming to convert multilamellar vesicles (MLVs) into 
small unilamellar vesicles (SUVs) having a size range around 100 nm. After probe 
sonication, the size of liposomes was decreased by approximately 95% or more 
(compared to size of initial MLVs), regardless of formulation (Figure 1a and Figure 2a). 
This indicates that drug inclusion and lipid composition did not retard size reduction and 
hence MLVs were successfully fragmented into nano-liposomes (100-200 nm) (Figure 
2a). Moreover, liposomes made from HSPC:Chol (1:1) had larger size than liposomes 
made from DPPC:Chol (1:1) or SPC:Chol (1:1). These results correlate with TEM images 
(Figure 1S) for the 1 mg/ml PX concentration for SPC, HSPC and DPPC liposomes 
respectively. The TEM-images were taken after probe-sonication and clearly showed that 
vesicles were SUVs. The size of SPC, HSPC and DPPC liposomes according to TEM 
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were approx. 125 nm, 175 nm and 155 nm respectively (Figure 1S). This indicates that 
size of sonicated vesicles was affected by lipid phase composition. Noteworthy, the effect 
of PX concentration on liposome size after sonication was minimal (Figure 2a). 
The polydispersity index (PI) for all liposomes was found to be below 0.3 
(Figure 2b), indicating that sonication has generated liposomes with relatively 
narrow size distribution, regardless of lipid type and drug concentration. 
However, an inconsistent effect of PX on polydispersity of the liposome 
vesicles was shown in Figure 2b as it is difficult to correlate PX concentration 
with the PI value, regardless of phospholipid type. Overall, the low PI for all 
formulations indicates that the sonication time selected was appropriate and 
no further size reduction was required.  
Zeta Potential Analysis Before Sonication  
The zeta potential of all liposome formulations before sonication were in the negative 
range (Figure 3a). The average zeta potential of PX-free SPC-liposomes was -1.82 mV ± 
0.09 which increased to -3.57 mV ± 0.28 upon inclusion of 0.1 mg/ml paclitaxel (P<0.05).  
However, inclusion of higher concentrations of paclitaxel tended to reduce the charge 
intensity (Figure 3a). Overall, only a slight or no difference in zeta potential values were 
observed when drug-free liposomes were compared to liposomes having the highest PX 
concentration (i.e. 1mg/ml). It is possible that changes in zeta potential are related to 
changes in the VMD of liposomes (Ofir et al., 2007, Elhissi et al., 2013). Further research 
is required to understand why the negative zeta potential tended to increase at low drug 
concentration and revert to the original value upon inclusion of higher drug 
concentrations.  
Zeta Potential Analysis After Sonication  
 
14 
The zeta potential of probe-sonicated liposomes was significantly lower than that of 
liposomes before size reduction, regardless of formulation. Furthermore, for SPC and 
HSPC-made liposomes, significant effects (P<0.05) of drug concentration on the zeta 
potential were observed (Figure 3b). For HSPC or SPC liposomes at low drug 
concentrations (0.1 or 0.3 mg/ml), the zeta potential was approximate to neutrality (i.e. 
0.00 mV). In contrast, DPPC-made vesicles showed more negative values. This may 
indicate that DPPC-made nano-liposomes are the most stable vesicles among the 
liposome formulations after sonication as the electrostatic repulsion between negatively 
charged DPPC vesicles may reduce aggregation (Howard and Levin, 2010).  
The increased negativity of zeta potential for the PX-SPC and PX-HSPC 
liposomes as a result of increasing the drug concentration was only a slight 
trend. However, statistically significant differences between the formulations 
depending on the composition of phospholipid were observed (Figure 3b). 
Compared with liposomes prior to sonication (Figure 3a), the zeta potential 
of PX-free SPC-liposomes after sonication was almost neutral whereas the 
zeta potential of PX-SPC-liposomes containing the maximum drug 
concentration decreased in intensity by approximately 54% when compared 
to that of pre-sonicated PX-SPC liposomes (Figure 3a and b). This suggests 
that vesicle size has an effect on zeta potential values, agreeing with previous 
investigations (Howard and Levin, 2010). 
 
pH Measurement of Liposome Formulations 
The effect of drug concentration and lipid composition on the pH of liposomes was 
investigated. The pH of all SPC and HSPC liposomes was slightly acidic, while the pH 
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of DPPC-liposomes was neutral to slightly basic (Figure 4). It is worth mentioning that 
the pH of formulations increased by increasing PX concentration. For SPC-liposomes, 
the pH of PX-free liposomes was 6.06 ± 0.01 whereas the pH of liposomes having the 
maximum PX concentration was 6.72 ± 0.02 (P<0.05). Similarly, the pH of PX-free 
HSPC liposomes was 6.08 ± 0.03 while the pH of liposomes with maximum drug 
concentration was 6.84 ± 0.2 (P<0.05). The pH of formulations was the highest for DPPC 
liposomes followed by HSPC and then SPC formulations. The pH of SPC and HSPC-
liposomes increased gradually by increasing the drug concentration (P<0.05). However, 
the pH of DPPC-liposomes remained the same until 0.5 mg/ml PX concentration with no 
significant difference. It can be concluded that differences in the pH of liposome 
formulations made using different lipids at similar PX concentrations were minimal. The 
pH of DPPC liposomes seems to be the closest to that of the physiological fluids (pH 7.4). 
Thus, amongst the various phospholipids used in this study, DPPC seems to be the most 
appropriate excipient for manufacturing liposome delivery systems for the anticancer 
drug paclitaxel. 
 
Entrapment Efficiency of PX in Liposomes 
According to Figure 5a, the entrapment efficiency of PX decreased with the increase in 
drug concentration (P<0.05) and that was independent of phospholipid composition. For 
example, the entrapment efficiency of the drug in DPPC-liposomes was 92.3% ± 2.7 for 
0.1 mg/ml and decreased by 57% using 1 mg/ml PX concentration (35.3% ± 1.8) 
(P<0.05). However, the entrapment efficiency in DPPC liposomes was generally higher 
than that in SPC and HSPC vesicles (Figure 5a). It is worth to mention that the difference 
in zeta potential with different PX concentrations may correlate with the different 
entrapment efficiencies using different lipid compositions. Figure 3b clearly 
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demonstrates that higher drug concentrations have conferred more negative surface 
charge on the DPPC liposomes. The ability of higher drug concentrations to exert that 
effect on SPC and HSPC vesicles was less, which correlates well with the entrapment 
efficiency findings. This gives a strong indication that the accommodation of paclitaxel 
within the liposome bilayers was responsible for the negative zeta potential values of 
DPPC vesicles. 
Figure 5b represents the amount of drug entrapped in 10 ml of liposome 
formulation. The amount of PX entrapped in the formulations was dependent 
on the composition of phospholipid and drug concentration. However, in all 
formulations the amount of entrapped PX increased as the drug concentration 
was increased. However, this increase was not significant at high durg 
concentrations (i.e. formulations contain 5 and 10 mg per 10 ml, figure 5b), 
displaying a plateau phase. This indicates that a maximum interaction 
between the drug and the phospholipid was reached and liposomes bilayers 
could not entrap more drug.  
HSPC-liposomes had less entrapment efficiency than that of SPC and DPPC-
liposomes (Figure 5a) (P<0.05). The plateau phase was reached at HSPC-
liposomes formulation of 5 mg PX loaded to 10 ml but entrapped only 2 mg. 
The formulation could not entrap PX efficiently with the highest drug 
concentration as compared to that of lower drug concentrations investigated. 
Similarly, DPPC-liposomes displayed an increase in the entrapped PX by 
increasing its initial loaded concentrations; with the highest PX concentration 
(10 mg /10 ml), the amount of drug entrapped was around 3.5 mg, which was 
higher than the maximum amount of drug entrapped in SPC or HSPC-made 
liposomes of the same loaded drug concentrations (figure 5b). According to  
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Table 1 which shows the correlating mol% entrapment values of PX, it is 
noticeable that entrapment findings for DPPC-liposomes (4.2 mol% at the 
maximum concentration) are slightly higher than those of the previously 
reported conventional liposomes (3 mol% in general) (Koudelka and 
Turánek, 2012); this might be due to the difference in the preparation method 
in this study adopting ethanol-based proliposome technology. Accordingly, 
further investigation is suggested to establish any possible effect of traces of 
ethanol on the entrapment efficiency of PX in liposomes prepared by ethanol-
based proliposome technology.  
Previous studies suggested that the molecular interaction between PX and 
lipid was facilitated by including cholesterol in the DPPC/PX mixed bilayers; 
this made a more stable tertiary system of paclitaxel, cholesterol and DPPC 
(Zhao et al., 2007). Cholesterol containing liposomes are generally more rigid 
and stable than liposomes made from phospholipid alone. DPPC-liposomes 
possess two thermal transitions: a sharp acyl chain melting transition 
temperature of 42.3 °C and a pre-transition temperature of 35.4°C (Zhao et 
al., 2007). Incorporation of PX can eliminate the pre-transition temperature 
without changing the main phase transition temperature, leading to a flexible 
bilayer (Zhao et al., 2007). PX is localized in C1-C8 carbon atoms of the acyl 
chain i.e. in the outer hydrophobic bilayer zone of DPPC liposomes and binds 
to the carbon atoms of DPPC by its C13 side chain, which is hydrophobic due 
to the presence of two aromatic rings (Balasubramanian and Straubinger, 
1994, Zhao et al., 2007).  
It has also been found that the stability of PX in saturated phospholipids is 
dependent on the chain length, with DPPC (16:0), (number of carbons in the 
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fatty acid chains and the degree of unsaturation), liposomes being more 
capable of entrapping higher proportions of paclitaxel than HSPC (18:0) 
liposomes (Zhao and Feng, 2004). The interaction between phospholipid and 
PX has been reported to be nonspecific and dependent on the hydrophobic 
binding or van der Waals forces. The stronger van der Waals interactions in 
the longer chain can hinder the movement of paclitaxel in the bilayers. This 
forms unstable systems when compared to phospholipids with shorter acyl 
chain (Zhao and Feng, 2004). This may explain the higher entrapment 
efficiency using DPPC (shorter chain) liposomes compared to HSPC vesicles. 
DPPC possesses a first-order phase transition, a transition between liquid-
expanded and liquid-condensed states, whereas HSPC possess only liquid-
condensed phase. This may be due to the higher hydrophobicity of longer acyl 
chain phospholipids (of HSPC) and the lower possibility to exist in the tilted 
liquid-expanded state due to repulsive interactions between water molecules 
at the interface (Zhao and Feng, 2004, Zhao and Feng, 2005). This might also 
explain the lower entrapment efficiency of HSPC compared to that of DPPC. 
Some studies have suggested that naturally occurring or unsaturated 
phospholipid such as SPC can entrap hydrophobic drugs more efficiently 
compared to HSPC due to their low gel to liquid-crystalline phase transition 
temperature (Tm= -20°C) (Darwis and Kellaway, 2001, Kan et al., 2011). 
The liposomes prepared from this type of phospholipid along with 
cholesterol, are flexible enough to entrap greater proportions of the 
hydrophobic molecules (Kirby et al., 1980, Senior and Gregoriadis, 1982, 
Zhang et al., 2005). Thus, liposomes prepared from HSPC liposomes are 
highly rigid and can limit the penetration of hydrophobic drugs. However, 
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DPPC-liposomes have shown high molecular interactions with PX due to 
their first-order phase transition behaviour (Zhao and Feng, 2004, Zhao and 
Feng, 2005). It has also been shown that PX interaction with lipid bilayers 
causes an increase in the surface charge intensity of the liposomes. This 
property is dependent on high molecular interactions between PX and 
phospholipids. Negative charge may increase the physical stability of 
liposomes by minimizing their fusion and aggregation (Kan et al., 2011). 
Thus, the difference in zeta potential with different PX concentrations may 
correlate with the different entrapment efficiency using liposome 
formulations with different lipid compositions. Figure 3b and Figure 5b 
clearly represented that higher drug concentrations have conferred more 
negative surface charge on the DPPC liposomes. The ability of higher drug 
concentrations to exert that effect on SPC and HSPC vesicles was 
comparatively less, which correlates well with the entrapment efficiency 
findings.  
Cytotoxicity Studies  
The cytotoxicity of liposomes loaded with a range of paclitaxel concentrations against 
U87-MG grade IV glioma and SVG-P12 glial cell lines was determined using the MTT 
assay. Figure 6 shows the effect of liposome formulations on the viability of U87-MG 
and SVG-P12 cells by plotting the concentrations in log-scale. Cell viabilities of both cell 
lines with drug-free liposomes increased by increasing concentrations regardless 
phospholipid type (P<0.05). This indicates that the preparation methods (i.e. the presence 
of traces of ethanol and the probe sonication) had no apparent effect on the cytotoxicity 
of the prepared formulations.  In contrast, the cell viability of both U87 and SVG cell 
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lines was decreased by approximately 95% (P<0.05) when treated with 1500 nM of 
Paclitaxel. 
For U87, Paclitaxel was responsible for the reduction in cell growth by 
approximately 97% (viability= 3.24% ± 0.45) with the highest concentration 
(1500 nM) (P<0.05). Cytotoxicity of paclitaxel alone was also higher than 
paclitaxel in liposome formulations by approximately 17%, 42% and 3% 
when using SPC, HSPC and DPPC respectively (P<0.05) (Figure 6a). 
Nevertheless, PX-DPPC-liposomes showed higher cytotoxicity than PX-
SPC-liposomes and PX-HSPC-liposomes by approximately 16% and 39% 
respectively when using 1500 nM loaded paclitaxel (P<0.05). High 
cytotoxicity of PX-DPPC-liposomes might be explained by the higher 
amount of paclitaxel entrapped in their vesicles compared to that of SPC and 
HSPC formulations (Figure 5). The reduced cytotoxicity of paclitaxel in 
liposome formulations as compared to free paclitaxel might be attributed to 
sustained drug release upon using liposomes (Figure 2S), or because of the 
nutritional values of phospholipid and cholesterol of liposomes. These results 
are confirmed by the IC50 of paclitaxel-loaded liposomes and paclitaxel 
against U87-MG cells (Table 2). 
Paclitaxel was responsible for the reduction in SVG cell growth by 
approximately 91% (cell viability of 9.38% ± 1.05) at the highest 
concentration. However, cytotoxicity of paclitaxel was higher than all 
paclitaxel loaded liposomes (P<0.05). The results indicate that liposomal 
formulations of paclitaxel are significantly less toxic (P<0.05) to glial cells 
(SVG-P12) than to U87-MG cells by approximately 35%, 18% or 40% when 
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treated with paclitaxel-loaded SPC-liposomes, HSPC-liposomes or DPPC-
liposomes respectively (Figure 6, Table 2).  
The less toxic trend of PX-liposomes formulations may be attributed to the 
sustained release of paclitaxel from the loaded liposomes contacting the cells 
and medium (Crosasso et al., 2000, Yang et al., 2007). Furthermore, it has 
been indicated that incorporating cholesterol in lipid bilayers increased the 
stability of liposomes and resulted in slower release of paclitaxel (Crosasso 
et al., 2000). Accordingly, increased IC50 of the PX-liposomes indicates that 
they were less toxic than paclitaxel (Table 2), which might be attributed to 
the fact that paclitaxel was retained within the phospholipid bilayers or 
attached to the surface of liposomes. This suggests that ethanol-based 
proliposome technology has successfully generated liposomes having 
sustained release properties by demonstrating a depot effect; part of paclitaxel 
is stored in the lipid bilayer as a depot, so the larger the depot, the longer the 
action of paclitaxel (Horowitz et al., 1992, Song et al., 2006). This also 
indicates that paclitaxel-loaded liposomes having a size of approximately 100 
to 200 nm would remain stable in biological environments; however, further 
studies should be conducted in vivo to find if a correlation with in vitro 
findings can be established.  
In general, liposomal formulations were also toxic to the SVG-P12 cells, 
especially for SPC-liposomes, HSPC-liposomes as their IC50 were more than 
2000 nM (Table 2). This implies that the liposomal formulations would need 
more than 2000 nM paclitaxel to kill 50% of SVG-P12 cells. Thus, IC50 of 
these liposome formulations was not determined. Paclitaxel has been found 
to be toxic to a wide variety of human cell lines such as malignant brain 
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tumour cells (U87-MG, U373, H80 and D324), breast adenocarcinoma 
(MCF-7), lung carcinoma (A549), cervical carcinoma (HeLa), colon 
adenocarcinoma (HT-29), ovarian adenocarcinoma (OVG-1), pancreatic 
adenocarcinomas (PC-Sh and PC-Zd), and rat brain tumour cell lines (9L and 
F98) (Liebmann et al., 1993, Cahan et al., 1994). Paclitaxel acts as an 
inhibitor of cell proliferation in vitro by interfering with the cell cycle 
development; it works by blocking the cell cycle at G2/M phase and altering 
the arrangement of spindle microtubules thereby causing cell death (De 
Brabander et al., 1981, Jordan et al., 1993, Straubinger et al., 2004). Similar 
anti-mitotic mechanism, upon treatment with paclitaxel, may have taken 
place, suggesting the decrease in viability of U87-MG and SVG-P12 cell 
lines.  
SVG-P12 cells showed less sensitivity to paclitaxel and paclitaxel-loaded 
liposomes than U87-MG cells. This may be due to the reason that the rate at 
which tumour cells are killed is dependent on their growth curve. Growth 
curve analysis of the cell lines plays a crucial role in understanding the cell 
proliferation and effect of anti-tumour agents on them. U87-MG cells reached 
high confluency (80-90%) in 2 days while SVG-P12 cells achieved the 
similar confluency in 4-5 days, for further sub-culturing of the cells. The 
growth and division of normal cells such as SVG-P12, in tissue culture 
conditions, are similar to that of U87-MG cells. However, the growth rate of 
normal cells decreases once they cover the bottom of the culture flask and 
remain as a monolayer. Growth inhibition may be caused by the exhaustion 
of growth factors in the medium. On the other hand, glioma cells continue to 
grow until they overlap with surrounding cells and form clumps. This may be 
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because they are unresponsive to the signals that cause the cessation of growth 
and division of their normal counterparts. This might explain the rapid 
decrease in the viability of U87-MG cells as compared to that of SVG-P12 
cells when treated with paclitaxel and liposome formulations (Karp, 2010).  
Drug-free formulations did not show any toxic effect on glioma as well as 
normal glial cell lines. Similarly, studies have shown that drug-free liposomes 
displayed non-toxic effect or effect equal to that of negative control on both 
cancer and normal cells in vitro (Al-Suwayeh et al., 1996, Graeser et al., 
2009). This may be due to that liposomes are prepared from naturally 
occurring materials such as phospholipids and cholesterol which are major 
constituents of biological membranes essential for cellular functions. 
Phosphatidylcholine forms a major component of the cell membranes and are 
found in the exoplasmic membrane leaflets. In fact, liposome vesicles might 
enhance the efficacy of the drugs by binding to the cells and releasing the 
therapeutic molecules in a sustained manner (Lasic, 1995, Al-Suwayeh et al., 
1996, Liu et al., 2013). 
Conclusions 
In this study, paclitaxel-loaded liposomes were prepared using ethanol-based 
proliposome technology. The influence of lipid composition (SPC:Chol, HSPC:Chol and 
DPPC:Chol in equimolar ratio) on the physicochemical properties of formulations, 
entrapment efficiency of paclitaxel in the liposomes and the cytotoxicity of the 
formulations were investigated. MLVs generated as a result of hydrating the 
proliposomes were successfully fragmented into nano-sized liposomes (100-200 nm) 
using probe-sonication for 10 min. The PI of all the formulations was below 0.3, 
indicating that sonication time selected was appropriate to form homogenous liposomes. 
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DPPC-liposomes had more intense surface charge upon using higher paclitaxel 
concentrations and the pH of DPPC liposomes was found to be the closest to the pH of 
physiological fluids (pH 7.4) making DPPC liposomes potentially highly appropriate 
vehicles for the anticancer drug paclitaxel. In addition, entrapment of paclitaxel in DPPC 
liposomes was generally higher than that in SPC or HSPC vesicles.  
The cytotoxicity of paclitaxel-loaded liposomes against U87-MG (grade IV 
glioma) and SVG-P12 glial cell lines was determined using MTT assay. It 
was observed that paclitaxel alone was more toxic to U87-MG and SVG-P12 
cells than paclitaxel in liposome formulations. PX-DPPC-liposomes showed 
higher cytotoxicity than PX-SPC and PX-HSPC formulations. The results 
were in correlation with the entrapment efficiency findings. Noteworthy, all 
liposomal formulations of PX had higher selective cytotoxicity to the 
malignant U87 cells compared to PX alone. Overall, this study has 
demonstrated that ethanol-based proliposomes, generating vesicles with a 
size of approximately 100 to 200 nm, made of DPPC and cholesterol may 
have a great potential to be used as an anticancer carrier. The results suggest 
that liposomes prepared by ethanol-based proliposome technology are able to 
act as potential nanocarriers of poorly water-soluble anticancer drugs (e.g. 
paclitaxel). However, comprehensive stability studies of such liposomes in 
several storage conditions are currently under investigation. Ethanol-based 
proliposome technology will be of great interest for the development of 
delivery systems to overcome challenging biological barriers such as Blood 
Brian Barrier (BBB). Such liposomal systems may comprise phospholipids 
attached to targeting moieties (e.g. folate), long circulating moieties such as 
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polyethylene glycol chains or/and even permeability enhancers such fatty 
acid chains. These strategies will be part of future investigations. 
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Table 1. Lipids and paclitaxel contents of liposomal formations. 
Initial PX 
concentratio
ns in 
liposomal 
formulation  
SPC:Chol (1:1) HSPC:Chol (1:1) DPPC:Chol (1:1) 
Loading 
SPC:Chol:P
X 
(mol ratio) 
Loaded to 
formulatio
n 
PX/Lipid 
(%mol) 
In final 
liposome 
formulation 
PX/Lipid 
(%mol)* 
Loading 
HSPC:Chol:
PX 
(mol ratio) 
Loaded to 
formulation 
PX/Lipid 
(%mol) 
In final 
liposome 
formulation 
PX/Lipid 
(%mol)* 
Loading 
DPPC:Chol:
PX 
(mol ratio) 
Loaded to 
formulatio
n PX/Lipid 
(%mol) 
In final 
liposome 
formulation 
PX/Lipid 
(%mol)* 
0.1 mg/ml 1:1:0.028 1.4 1.0 1:1:0.028 1.4 0.84 1:1:0.027 1.3 1.2 
0.3 mg/ml 1:1:0.084 4.0 2.9 1:1:0.084 4.0 2.1 1:1:0.081 3.9 3.0 
0.5 mg/ml 1:1:0.14 6.5 3.1 1:1:0.14 6.5 2.6 1:1:0.13 6.1 3.7 
1.0 mg/ml 1:1:0.28 12.3 3.4 1:1:0.28 12.3 3.1 1:1:0.27 11.9 4.2 
* After filtration 
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Table 2.  IC50 (nM of paclitaxel-loaded liposomes and paclitaxel SVG-P12 and U87-
MG cells. (n=3 ± SD) 
 
Formulation  
 
IC50 Value (nM) ± SD for 
SVG-P12 cells 
IC50 Value (nM) ± SD for 
U87-MG cells 
Paclitaxel 44.3 ± 9.2 23.0 ± 6.1 
DPPC+paclitaxel 936.7 ± 57.8 61.3 ± 7.9 
SPC+paclitaxel >2000 245.2 ± 21.4 
HSPC+paclitaxel >2000 1030.1 ± 123.6 
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Figure 1. (a) Volume median diameter (VMD) and (b) Size distribution (Span) of 
liposomes generated from ethanol-based proliposome formulations with a range of 
paclitaxel concentrations (n=3 ± SD).  
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Figure 2. (a) Size (Zaverage) of liposomes after probe sonication, (b) PI of liposomes 
after probe sonication with a range of paclitaxel concentrations (n=3 ± SD).  
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Figure 3.  Zeta potential of liposomes (a) before probe sonication and (b) after probe 
sonication with a range of paclitaxel concentrations (n=3 ± SD) 
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Figure 4.  pH of liposomes after probe sonication with a range of paclitaxel 
concentrations (n=3 ± SD). 
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Figure 5. (a) Entrapment efficiency of liposomes and (b) The amount of paclitaxel 
entrapped per 10 ml of formulation (N=3 ± SD). 
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Figure 6. Viability of (a) U87-MG and (b) SVG-P12 cell line tested with increasing 
concentrations of different formulations in 96-well plates. (n=18, N=3 ± SD) 
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Figure captions 
 
Figure 1. (a) Volume median diameter (VMD) and (b) Size distribution (Span) of 
liposomes generated from ethanol-based proliposome formulations with a range of 
paclitaxel concentrations (n=3 ± SD). 
Figure 2. (a) Size (Zaverage) of liposomes after probe sonication, (b) PI of liposomes 
after probe sonication with a range of paclitaxel concentrations (n=3 ± SD).  
Figure 3.  Zeta potential of liposomes (a) before probe sonication and (b) after probe 
sonication with a range of paclitaxel concentrations (n=3 ± SD) 
Figure 4.  pH of liposomes after probe sonication with a range of paclitaxel 
concentrations (n=3 ± SD). 
Figure 5. (a) Entrapment efficiency of liposomes and (b) The amount of paclitaxel 
entrapped per 10 ml of formulation (N=3 ± SD). 
Figure 6. Viability of (a) U87-MG and (b) SVG-P12 cell line tested with increasing 
concentrations of different formulations in 96-well plates. (n=18, N=3 ± SD) 
 
 
 
 
